Do analysts recommend THAR or XFOR?

X4 Pharmaceuticals has a consensus price target of $9.70, suggesting a potential upside of 151.95%. Given X4 Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe X4 Pharmaceuticals is more favorable than Tharimmune. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 X4 Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Does the media favor THAR or XFOR?

In the previous week, X4 Pharmaceuticals had 1 more articles in the media than Tharimmune. MarketBeat recorded 2 mentions for X4 Pharmaceuticals and 1 mentions for Tharimmune. X4 Pharmaceuticals' average media sentiment score of 1.87 beat Tharimmune's score of 1.25 indicating that X4 Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tharimmune 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive X4 Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts recommend LXEO or THAR?

Lexeo Therapeutics currently has a consensus target price of $18.75, suggesting a potential upside of 302.36%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Lexeo Therapeutics is more favorable than Tharimmune. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexeo Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, LXEO or THAR?

Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lexeo Therapeutics N/A N/A -$99.96M -$1.45 N/A Tharimmune N/A N/A -$12.20M -$3.99 N/A

Is LXEO or THAR more profitable?

Lexeo Therapeutics' return on equity of -47.48% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Lexeo Therapeutics N/A -47.48% -41.72% Tharimmune N/A -588.45% -264.41%

Does the media refer more to LXEO or THAR?

In the previous week, Lexeo Therapeutics had 4 more articles in the media than Tharimmune. MarketBeat recorded 5 mentions for Lexeo Therapeutics and 1 mentions for Tharimmune. Tharimmune's average media sentiment score of 1.25 beat Lexeo Therapeutics' score of 0.63 indicating that Tharimmune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tharimmune 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer THAR or SNDL?

SNDL has a consensus target price of $5.00, suggesting a potential upside of 301.61%. Given SNDL's stronger consensus rating and higher probable upside, analysts plainly believe SNDL is more favorable than Tharimmune. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SNDL 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, THAR or SNDL?

SNDL has higher revenue and earnings than Tharimmune. SNDL is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tharimmune N/A N/A -$12.20M -$3.99 N/A SNDL $937.39M 0.34 -$11.29M -$0.03 N/A

Is THAR or SNDL more profitable?

Tharimmune has a net margin of 0.00% compared to SNDL's net margin of -1.19%. SNDL's return on equity of -1.02% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Tharimmune N/A -588.45% -264.41% SNDL -1.19% -1.02% -0.85%

Does the media refer more to THAR or SNDL?

In the previous week, SNDL had 1 more articles in the media than Tharimmune. MarketBeat recorded 2 mentions for SNDL and 1 mentions for Tharimmune. Tharimmune's average media sentiment score of 1.25 beat SNDL's score of 0.37 indicating that Tharimmune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tharimmune 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SNDL 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ORGO or THAR?

Organogenesis currently has a consensus price target of $5.75, indicating a potential upside of 140.59%. Given Organogenesis' stronger consensus rating and higher probable upside, research analysts clearly believe Organogenesis is more favorable than Tharimmune. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organogenesis 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ORGO or THAR more profitable?

Tharimmune has a net margin of 0.00% compared to Organogenesis' net margin of -0.84%. Organogenesis' return on equity of 9.63% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Organogenesis -0.84% 9.63% 4.76% Tharimmune N/A -588.45% -264.41%

Does the media prefer ORGO or THAR?

In the previous week, Organogenesis had 2 more articles in the media than Tharimmune. MarketBeat recorded 3 mentions for Organogenesis and 1 mentions for Tharimmune. Organogenesis' average media sentiment score of 1.49 beat Tharimmune's score of 1.25 indicating that Organogenesis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tharimmune 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend THAR or PALI?

Palisade Bio has a consensus target price of $9.00, suggesting a potential upside of 361.54%. Given Palisade Bio's stronger consensus rating and higher probable upside, analysts clearly believe Palisade Bio is more favorable than Tharimmune. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Palisade Bio 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has preferable valuation and earnings, THAR or PALI?

Palisade Bio is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tharimmune N/A N/A -$12.20M -$3.99 N/A Palisade Bio N/A N/A -$16.78M -$1.01 N/A

Is THAR or PALI more profitable?

Palisade Bio's return on equity of -36.79% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Tharimmune N/A -588.45% -264.41% Palisade Bio N/A -36.79% -34.34%

Does the media refer more to THAR or PALI?

In the previous week, Palisade Bio had 4 more articles in the media than Tharimmune. MarketBeat recorded 5 mentions for Palisade Bio and 1 mentions for Tharimmune. Tharimmune's average media sentiment score of 1.25 beat Palisade Bio's score of 1.07 indicating that Tharimmune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tharimmune 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palisade Bio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tharimmune (THAR) Competitors

$1.94 -0.12 (-5.83%)

As of 07/24/2026

Compare

THAR vs. XFOR, LXEO, SNDL, ORGO, and PALI

Should you buy Tharimmune stock or one of its competitors? MarketBeat compares Tharimmune with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tharimmune include X4 Pharmaceuticals (XFOR), Lexeo Therapeutics (LXEO), SNDL (SNDL), Organogenesis (ORGO), and Palisade Bio (PALI). These companies are all part of the "pharmaceutical products" industry.

How does Tharimmune compare to X4 Pharmaceuticals?

Tharimmune (NASDAQ:THAR) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

Tharimmune has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Tharimmune has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -1,106.30%. X4 Pharmaceuticals' return on equity of -94.90% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%

1.2% of Tharimmune shares are held by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are held by institutional investors. 6.7% of Tharimmune shares are held by insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Tharimmune has higher earnings, but lower revenue than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
X4 Pharmaceuticals	$35.11M	10.34	-$79.20M	-$4.54	N/A

In the previous week, X4 Pharmaceuticals had 1 more articles in the media than Tharimmune. MarketBeat recorded 2 mentions for X4 Pharmaceuticals and 1 mentions for Tharimmune. X4 Pharmaceuticals' average media sentiment score of 1.87 beat Tharimmune's score of 1.25 indicating that X4 Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tharimmune	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
X4 Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

X4 Pharmaceuticals has a consensus price target of $9.70, suggesting a potential upside of 151.95%. Given X4 Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe X4 Pharmaceuticals is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

X4 Pharmaceuticals beats Tharimmune on 9 of the 15 factors compared between the two stocks.

How does Tharimmune compare to Lexeo Therapeutics?

Lexeo Therapeutics (NASDAQ:LXEO) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A

60.7% of Lexeo Therapeutics shares are held by institutional investors. Comparatively, 1.2% of Tharimmune shares are held by institutional investors. 2.0% of Lexeo Therapeutics shares are held by insiders. Comparatively, 6.7% of Tharimmune shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Lexeo Therapeutics' return on equity of -47.48% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-47.48%	-41.72%
Tharimmune	N/A	-588.45%	-264.41%

Lexeo Therapeutics currently has a consensus target price of $18.75, suggesting a potential upside of 302.36%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Lexeo Therapeutics is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lexeo Therapeutics has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market.

In the previous week, Lexeo Therapeutics had 4 more articles in the media than Tharimmune. MarketBeat recorded 5 mentions for Lexeo Therapeutics and 1 mentions for Tharimmune. Tharimmune's average media sentiment score of 1.25 beat Lexeo Therapeutics' score of 0.63 indicating that Tharimmune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexeo Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tharimmune	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lexeo Therapeutics beats Tharimmune on 9 of the 14 factors compared between the two stocks.

How does Tharimmune compare to SNDL?

Tharimmune (NASDAQ:THAR) and SNDL (NASDAQ:SNDL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

In the previous week, SNDL had 1 more articles in the media than Tharimmune. MarketBeat recorded 2 mentions for SNDL and 1 mentions for Tharimmune. Tharimmune's average media sentiment score of 1.25 beat SNDL's score of 0.37 indicating that Tharimmune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tharimmune	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SNDL	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tharimmune has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market. Comparatively, SNDL has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

SNDL has higher revenue and earnings than Tharimmune. SNDL is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
SNDL	$937.39M	0.34	-$11.29M	-$0.03	N/A

Tharimmune has a net margin of 0.00% compared to SNDL's net margin of -1.19%. SNDL's return on equity of -1.02% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
SNDL	-1.19%	-1.02%	-0.85%

1.2% of Tharimmune shares are owned by institutional investors. 6.7% of Tharimmune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

SNDL has a consensus target price of $5.00, suggesting a potential upside of 301.61%. Given SNDL's stronger consensus rating and higher probable upside, analysts plainly believe SNDL is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SNDL	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

SNDL beats Tharimmune on 9 of the 15 factors compared between the two stocks.

How does Tharimmune compare to Organogenesis?

Organogenesis (NASDAQ:ORGO) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 1.2% of Tharimmune shares are owned by institutional investors. 18.8% of Organogenesis shares are owned by insiders. Comparatively, 6.7% of Tharimmune shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Organogenesis has higher revenue and earnings than Tharimmune. Organogenesis is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$564.17M	0.55	$37.03M	-$0.19	N/A
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A

In the previous week, Organogenesis had 2 more articles in the media than Tharimmune. MarketBeat recorded 3 mentions for Organogenesis and 1 mentions for Tharimmune. Organogenesis' average media sentiment score of 1.49 beat Tharimmune's score of 1.25 indicating that Organogenesis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organogenesis	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tharimmune	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tharimmune has a net margin of 0.00% compared to Organogenesis' net margin of -0.84%. Organogenesis' return on equity of 9.63% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-0.84%	9.63%	4.76%
Tharimmune	N/A	-588.45%	-264.41%

Organogenesis currently has a consensus price target of $5.75, indicating a potential upside of 140.59%. Given Organogenesis' stronger consensus rating and higher probable upside, research analysts clearly believe Organogenesis is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Organogenesis has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market.

Summary

Organogenesis beats Tharimmune on 12 of the 15 factors compared between the two stocks.

How does Tharimmune compare to Palisade Bio?

Tharimmune (NASDAQ:THAR) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

Palisade Bio's return on equity of -36.79% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Palisade Bio	N/A	-36.79%	-34.34%

1.2% of Tharimmune shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 6.7% of Tharimmune shares are held by insiders. Comparatively, 0.1% of Palisade Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Palisade Bio is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
Palisade Bio	N/A	N/A	-$16.78M	-$1.01	N/A

In the previous week, Palisade Bio had 4 more articles in the media than Tharimmune. MarketBeat recorded 5 mentions for Palisade Bio and 1 mentions for Tharimmune. Tharimmune's average media sentiment score of 1.25 beat Palisade Bio's score of 1.07 indicating that Tharimmune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tharimmune	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palisade Bio	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Palisade Bio has a consensus target price of $9.00, suggesting a potential upside of 361.54%. Given Palisade Bio's stronger consensus rating and higher probable upside, analysts clearly believe Palisade Bio is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

Tharimmune has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market.

Summary

Palisade Bio beats Tharimmune on 10 of the 14 factors compared between the two stocks.

Get Tharimmune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding THAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

THAR vs. The Competition

Export

Metric	Tharimmune	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$73.20M	$3.67B	$6.88B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-0.49	21.11	27.00	23.71
Price / Sales	N/A	164.10	492.66	73.79
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	2.85	7.88	10.28	6.07
Net Income	-$12.20M	$23.81M	$3.60B	$331.84M
7 Day Performance	-15.65%	-3.79%	-1.25%	-1.53%
1 Month Performance	-27.20%	-2.59%	-0.35%	-2.46%
1 Year Performance	29.85%	32.85%	18.41%	13.66%

Tharimmune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
THAR Tharimmune	0.0745 of 5 stars	$1.94 -5.8%	N/A	+34.6%	$73.20M	N/A	N/A	2	Positive News
XFOR X4 Pharmaceuticals	2.877 of 5 stars	$3.81 -2.4%	$9.70 +154.9%	+110.4%	$358.89M	$35.11M	N/A	80	News Coverage Positive News
LXEO Lexeo Therapeutics	1.9596 of 5 stars	$4.57 -3.6%	$18.75 +310.3%	+27.0%	$358.84M	N/A	N/A	58	News Coverage Positive News
SNDL SNDL	3.3562 of 5 stars	$1.31 +1.2%	$5.00 +283.1%	-19.2%	$335.90M	$937.39M	N/A	2,751	Upcoming Earnings
ORGO Organogenesis	1.9498 of 5 stars	$2.62 +5.0%	$5.75 +119.9%	-49.7%	$335.21M	$564.17M	N/A	950	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:THAR) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tharimmune (THAR) Competitors

THAR vs. XFOR, LXEO, SNDL, ORGO, and PALI

How does Tharimmune compare to X4 Pharmaceuticals?

Summary

How does Tharimmune compare to Lexeo Therapeutics?

Summary

How does Tharimmune compare to SNDL?

Summary

How does Tharimmune compare to Organogenesis?

Summary

How does Tharimmune compare to Palisade Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

THAR vs. The Competition

Tharimmune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tharimmune (THAR) Competitors

THAR vs. XFOR, LXEO, SNDL, ORGO, and PALI

How does Tharimmune compare to X4 Pharmaceuticals?

Which has more risk and volatility, THAR or XFOR?

Is THAR or XFOR more profitable?

Do insiders and institutionals hold more shares of THAR or XFOR?

Which has stronger valuation & earnings, THAR or XFOR?

Does the media favor THAR or XFOR?

Do analysts recommend THAR or XFOR?

Summary

How does Tharimmune compare to Lexeo Therapeutics?

Which has better valuation & earnings, LXEO or THAR?

Do insiders & institutionals have more ownership in LXEO or THAR?

Is LXEO or THAR more profitable?

Do analysts recommend LXEO or THAR?

Which has more risk & volatility, LXEO or THAR?

Does the media refer more to LXEO or THAR?

Summary

How does Tharimmune compare to SNDL?

Does the media refer more to THAR or SNDL?

Which has more risk & volatility, THAR or SNDL?

Which has better earnings & valuation, THAR or SNDL?

Is THAR or SNDL more profitable?

Do institutionals and insiders have more ownership in THAR or SNDL?

Do analysts prefer THAR or SNDL?

Summary

How does Tharimmune compare to Organogenesis?

Do institutionals & insiders believe in ORGO or THAR?

Which has stronger earnings and valuation, ORGO or THAR?

Does the media prefer ORGO or THAR?

Is ORGO or THAR more profitable?

Do analysts recommend ORGO or THAR?

Which has more risk & volatility, ORGO or THAR?

Summary

How does Tharimmune compare to Palisade Bio?

Is THAR or PALI more profitable?

Do institutionals and insiders hold more shares of THAR or PALI?

Which has preferable valuation and earnings, THAR or PALI?

Does the media refer more to THAR or PALI?

Do analysts recommend THAR or PALI?

Which has more volatility & risk, THAR or PALI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

THAR vs. The Competition

Tharimmune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools